IONIS PHARMACEUTICALS INC Intellectual Property Contracts & Agreements
22 Contracts & Agreements
- License Agreements (22 contracts)
- Research, Development, and License Agreement by and among the Registrant, F. Hoffmann-La Roche Ltd., and Hoffmann-La Roche Inc. dated as of September 26, 2023. Portions of this... (Filed With SEC on November 2, 2023)
- HTT Research, Development, Option and License Agreement among the Registrant, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., dated as of April. 8, 2013 (Filed With SEC on May 3, 2023)
- Amendment #8 to the Research, Development and License Agreement between the Registrant, Glaxo Group Limited and Glaxosmithkline Intellectual Property Development Limited, dated... (Filed With SEC on November 6, 2019)
- AMENDMENT #1 TO THE LICENSE AGREEMENT, DATED MAY 1ST, 2015 (Filed With SEC on May 9, 2017)
- AMENDMENT #7 TO THE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (Filed With SEC on May 5, 2016)
- AMENDMENT #1 TO HTT RESEARCH, DEVELOPMENT, OPTION AND LICENSE AGREEMENT (Filed With SEC on May 5, 2015)
- EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on November 7, 2014)
- Amendment #5 to the Research, Development and License Agreement among the Registrant, Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Limited dated June... (Filed With SEC on August 4, 2014)
- Amendment #4 to the Research, Development and License Agreement between the Registrant and Glaxo Group Limited dated April 10, 2014. Portions of this exhibit have been omitted and... (Filed With SEC on August 4, 2014)
- Amendment No. 3 to the Research, Development and License Agreement between the Registrant and Glaxo Group Limited dated July 10, 2013. Portions of this exhibit have been omitted... (Filed With SEC on August 4, 2014)
- HTT RESEARCH, DEVELOPMENT, OPTION AND LICENSE AGREEMENT AMONG ISIS PHARMACEUTICALS, INC., AND F. HOFFMANN-LA ROCHE LTD AND HOFFMANN-LA ROCHE INC. (Filed With SEC on August 6, 2013)
- AMENDMENT #2 TO RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (Filed With SEC on February 28, 2013)
- DMPK RESEARCH, DEVELOPMENT, OPTION AND LICENSE AGREEMENT BETWEEN ISIS PHARMACEUTICALS, INC., AND BIOGEN IDEC MA INC. (Filed With SEC on August 6, 2012)
- DEVELOPMENT, OPTION AND LICENSE AGREEMENT BETWEEN ISIS PHARMACEUTICALS, INC., AND BIOGEN IDEC INTERNATIONAL HOLDING LTD (Filed With SEC on May 9, 2012)
- AMENDMENT #1 TO RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (Filed With SEC on August 8, 2011)
- FIRSTAMENDMENT TOCOLLABORATION RESEARCH AND LICENSE AGREEMENT (Filed With SEC on November 5, 2010)
- AMENDMENTNO. 1 TO AMENDEDAND RESTATED LICENSE AGREEMENT (Filed With SEC on March 1, 2010)
- AMENDED &RESTATED LICENSE AGREEMENT (Filed With SEC on March 1, 2010)
- DRUGDEVELOPMENT AND LICENSE OPTION AGREEMENT BETWEEN ELILILLY AND COMPANY AND ISISPHARMACEUTICALS, INC. December 2,2009 (Filed With SEC on March 1, 2010)
- AMENDEDAND RESTATED LICENSE AGREEMENT (Filed With SEC on November 10, 2008)
- LICENSE AND RESEARCH AGREEMENT (Filed With SEC on May 12, 2008)
- COLLABORATIONAND LICENSE AGREEMENT between ISIS PHARMACEUTICALS, INC. and BRISTOL-MYERSSQUIBB COMPANY (Filed With SEC on August 9, 2007)
